(Q34403375)

1 August 2017

title

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors (English)

1 reference

1 August 2017

author

Nicholas J. Vogelzang

3

object named as

Nicholas Vogelzang

1 reference

1 August 2017

Carlos R Becerra

1

1 reference

1 August 2017

Paul Conkling

2

1 reference

1 August 2017

Hilary Wu

4

1 reference

1 August 2017

Shengyan Hong

5

1 reference

1 August 2017

Rajesh Narwal

6

1 reference

1 August 2017

Meina Liang

7

1 reference

1 August 2017

Fatemeh Tavakkoli

8

1 reference

1 August 2017

Naimish Pandya

9

1 reference

1 August 2017

publication date

23 August 2014

1 reference

Cancer Chemotherapy and Pharmacology

1 August 2017

published in

1 reference

1 August 2017

volume

74

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

917-925

1 reference

Creative Commons Attribution 4.0 International

1 August 2017

copyright license

start time

23 August 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.

6 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2567-9

Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2567-9

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2567-9

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209236

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

27 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2567-9

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25149088

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00280-014-2567-9

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference